- Halo Therapeutics Ltd is preparing for clinical trials into pivotal, cost-effective antiviral treatments for COVID-19, after discovering a molecule which changes the shape of the virus's spike protein and in so doing inhibits the virus’ ability to enter cells.
- Studies show the treatments are potentially 'pan-corona antivirals' in that they will work against all coronavirus strains - including the highly contagious 'UK (Kent)', 'South African' and 'Brazilian' variants.
- The company is preparing for clinical trials. If approved, the antivirals could be used by patients globally at the first sign of COVID-19 symptoms – stopping the virus in its tracks.
Newly launched British biotech company pioneers ground-breaking potential treatments for COVID-19
Press release issued: 13 April 2021
A team of top scientists from the University of Bristol have announced the formation of a new biotech company that is developing ground-breaking and newly patented potential treatments for coronavirus.
Further information
About Halo Therapeutics Ltd
Bristol-based biotech start-up Halo Therapeutics develops pan-coronavirus antivirals and anti-inflammatory therapies for coronavirus infection and is backed by private investors.
Find us on LinkedIn.